Ponaxen 45 mg contains Ponatinib, a potent tyrosine kinase inhibitor (TKI) designed for the treatment of Philadelphia chromosome–positive leukemias, including chronic, accelerated, or blast phase chronic myeloid leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL). Ponatinib selectively inhibits native and mutant forms of the BCR-ABL tyrosine kinase, including the T315I mutation, which is resistant to most other TKIs.

Ponaxen also targets additional kinases, including members of the VEGFR, PDGFR, FGFR, EPH receptor, SRC, KIT, RET, TIE2, and FLT3 families, contributing to its anti-tumor activity. By blocking abnormal kinase signaling, Ponaxen reduces tumor cell proliferation and survival in both hematologic and solid malignancies.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Ponaxen 45 mg is indicated for:

• Chronic Myeloid Leukemia (CML) – chronic, accelerated, or blast phases

• Philadelphia chromosome–positive Acute Lymphoblastic Leukemia (Ph+ ALL)

• Patients with T315I mutation resistant to other BCR-ABL inhibitors

Ponaxen is prescribed for patients with inadequate response to prior therapies or intolerance to other tyrosine kinase inhibitors.

Therapeutic Class

• Tyrosine Kinase Inhibitor (TKI)

Pharmacology and Mode of Action

Ponatinib selectively inhibits both native and mutant BCR-ABL kinases, including the T315I mutation. It also inhibits multiple other kinases involved in angiogenesis and tumor proliferation, such as VEGFR, PDGFR, FGFR, SRC family kinases, KIT, RET, TIE2, and FLT3.

By targeting these pathways, Ponaxen reduces tumor cell viability and proliferation and prevents disease progression in resistant leukemia cases.

Dosage and Administration

• Starting Dose: 45 mg once daily

• Dose Adjustment: Dose reduction to 15 mg may be considered in chronic phase CML patients achieving a major cytogenetic response, based on cardiovascular risk, side effects, BCR-ABL transcript levels, and treatment response

• Duration: Continue until disease progression or unacceptable toxicity

• Monitoring:

  • Cardiovascular status before and during therapy

  • Complete blood counts every 2 weeks for the first 3 months, then monthly

  • Liver function tests and blood pressure periodically

Special Populations:

• Elderly (>65 years): Higher likelihood of adverse reactions

• Hepatic Impairment: Use with caution; standard starting dose may be given

• Renal Impairment: No dose adjustment for CrCl >50 mL/min; caution if CrCl <50 mL/min

Pediatric Use: Safety and efficacy not established (<18 years)

Drug Interactions

• CYP3A4 Substrate: Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) may require dose reduction to 30 mg

• Strong CYP3A4 Inducers (e.g., carbamazepine, rifampicin, St. John’s Wort) should be avoided

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Contraindications

• Hypersensitivity to Ponatinib or any excipient

Side Effects

Common serious adverse reactions (>2%) include:

• Pneumonia, pancreatitis, abdominal pain

• Atrial fibrillation, myocardial infarction, peripheral arterial occlusive disease

• Anaemia, thrombocytopenia, febrile neutropenia

• Hypertension, cardiac failure, cerebrovascular accident

• Sepsis, acute kidney injury, urinary tract infection, elevated lipase

Precautions & Warnings

• Myelosuppression: Thrombocytopenia, neutropenia, anaemia; monitor closely

• Cardiovascular Risk: Arterial occlusions, heart failure, hypertension; monitor and manage proactively

• Hepatotoxicity: Monitor liver enzymes periodically; rare fatal hepatic failure

• Bleeding Risk: Severe hemorrhage may occur; evaluate patients promptly

• Hepatitis B Reactivation: Screen for HBV prior to treatment and monitor during therapy

Pregnancy & Lactation

• Use only if clearly necessary; animal studies show reproductive toxicity

• Breastfeeding should be discontinued during therapy

• No human data on fertility; animal studies show potential effects on female fertility

Overdose

• Supportive and symptomatic management

• Monitor ECG and vital signs; stop Ponaxen immediately in case of toxicity

Storage Conditions

Store below 30°C in a cool, dry place. Avoid exposure to temperatures above 40°C. Keep out of reach of children.